DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

Information source: Merck KGaA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis, Relapsing-Remitting

Intervention: Rebif (Interferon beta-1a) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Merck KGaA

Official(s) and/or principal investigator(s):
Medical Responsible, Study Director, Affiliation: Merck spol.s.r.o., Czech Republic

Summary

The study is planned to evaluate the cognitive functions in subjects with RRMS treated with interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.

Clinical Details

Official title: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Percentage of subjects with decreased/increased/stable cognition status (PASAT)

Secondary outcome:

Percentage of subjects with decreased/increased/stable fatigue (FDS)

Relationship between the cognition status, the fatigue status and the EDSS status

Relationship between the Rebif dosage used with cognition and fatigue status

Proportion of relapse-free subjects

Proportion of subjects with defined EDSS changes (decrease; no change; increase of 0.5 - 1.0; 1.5 - 2.0; 2.5 - 3.0; 3.0 or more points, respectively)

Proportion of subjects without either relapse, EDSS progression, cognition status decrease and fatigue increase

Number of Rebif doses not taken since the last study visit, and the reason of dose not taken

Proportion of subjects using the antidepressive or antifatigue medication

Detailed description: Besides the motor and sensory dysfunctions, the progression of cognitive decline is a frequent manifestation of RRMS. Fatigue is another important symptom of MS, and can negatively affect subject's Quality of life (QoL) and socio-economic functioning, including the ability to work, independent of the direct effects of disability. This is a phase IV observational, non-interventional, prospective, multicentric study to evaluate cognition in RRMS subjects treated with Rebif and its relationship to the fatigue and neurological dysfunction status. The study plans to enroll 300 subjects, across 14 centres in Czech Republic, who will be prescribed with Rebif according to its summary of product characteristics (SmPC). Assessment of cognitive and fatigue status will be done at baseline and follow-up visits at Months 3, 6, 12, 24. Subjects will be selected using the convenience method following the non-probability sampling. OBJECTIVES Primary Objective:

- To assess changes of cognition [measured by Paced Auditory Serial Addition Test

(PASAT)] in RRMS subjects treated with Rebif Secondary Objectives:

- To assess changes of fatigue [measured by Fatigue Descriptive Scale (FDS)] in RRMS

subjects treated with Rebif

- To assess a correlation between cognition, fatigue and neurological status in RRMS

subjects treated with Rebif

- To assess a relationship between Rebif dosage [22 mcg vs 44 mcg thrice a week (tiw)]

and cognition (PASAT)

- To assess a relationship between Rebif dosage (22 mcg vs 44 mcg tiw) and fatigue (FDS)

- To assess adherence to Rebif treatment

- To explore the use of antidepressive and antifatigue medicaments

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects diagnosed with RRMS

- Subjects eligible for treatment with Rebif as per SmPC, the Czech local guidelines

and the actual Health insurance policy.

- Subjects 18-65 years of age

- Subjects with EDSS score < 4

- Subjects who are willing and able to give informed consent

Exclusion Criteria:

- Treatment with Rebif for more than 24 months prior the informed consent form has been

obtained.

- Subjects with history of hypersensitivity to natural or recombinant interferon-β, or

to any excipients

- Female subject who is pregnant or breast feeding and/or planning to become pregnant

- Subjects with current severe depression and/or suicidal ideation

- Any contraindication for Rebif therapy as per SmPC

- Subjects with severe disability and/or any neurologic or psychiatric condition that

may interfere with test performance

- Prior treatment with interferon beta-1a i. m. or interferon beta-1b or glatiramer

acetate.

Locations and Contacts

Neurologicka klinika FNBB, Brno, Czech Republic

Neurologicka klinika, Fakultní nemocnice U Sv. Anny, Brno, Czech Republic

Neurologicke oddeleni KN., Ceske Budejovice, Czech Republic

Neurologicka klinika Fakultní nemocnice, Hradec Kralove, Czech Republic

Neurologicka klinika Fakultní nemocnice, Motol, Czech Republic

Neurologicka klinika, Fakultní nemocnice, Olomouc, Czech Republic

Neurologicka klinika Fakultní nemocnice, Ostrava, Czech Republic

Neurologicke oddeleni KN, Pardubice, Czech Republic

Neurologicka klinika Fakultní nemocnice, Plzeň, Czech Republic

Neurologicka klinika FNKV, Praha, Czech Republic

Neurologicka klinika, Fakultní Thomayerovy nemocnice, Praha, Czech Republic

Neurologicke oddeleni NsP, Teplice, Czech Republic

Neurologicke oddeleni, Baťova nemocnice, Zlín, Czech Republic

Additional Information

Starting date: May 2009
Last updated: September 5, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017